Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Rapid Cloning of Novel Rhesus Adenoviral Vaccine Vectors.

Abbink P, Kirilova M, Boyd M, Mercado N, Li Z, Nityanandam R, Nanayakkara O, Peterson R, Larocca RA, Aid M, Tartaglia L, Mutetwa T, Blass E, Jetton D, Maxfield LF, Borducchi EN, Badamchi-Zadeh A, Handley S, Zhao G, Virgin HW, Havenga MJ, Barouch DH.

J Virol. 2018 Feb 26;92(6). pii: e01924-17. doi: 10.1128/JVI.01924-17. Print 2018 Mar 15.

2.

Rapid generation of a well-matched vaccine seed from a modern influenza A virus primary isolate without recourse to eggs.

Hartgroves LC, Koudstaal W, McLeod C, Moncorgé O, Thompson CI, Ellis J, Bull C, Havenga MJ, Goudsmit J, Barclay WS.

Vaccine. 2010 Apr 9;28(17):2973-9. doi: 10.1016/j.vaccine.2010.02.012. Epub 2010 Feb 25.

PMID:
20188682
3.

Adenovirus serotype 5 infects human dendritic cells via a coxsackievirus-adenovirus receptor-independent receptor pathway mediated by lactoferrin and DC-SIGN.

Adams WC, Bond E, Havenga MJ, Holterman L, Goudsmit J, Karlsson Hedestam GB, Koup RA, Loré K.

J Gen Virol. 2009 Jul;90(Pt 7):1600-10. doi: 10.1099/vir.0.008342-0. Epub 2009 Mar 12.

PMID:
19282435
4.

Fiber-chimeric adenoviruses expressing fibers from serotype 16 and 50 improve gene transfer to human pancreatic adenocarcinoma.

Kuhlmann KF, van Geer MA, Bakker CT, Dekker JE, Havenga MJ, Elferink RP, Gouma DJ, Bosma PJ, Wesseling JG.

Cancer Gene Ther. 2009 Jul;16(7):585-97. doi: 10.1038/cgt.2009.4. Epub 2009 Jan 30.

PMID:
19180144
5.

Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys.

Liu J, O'Brien KL, Lynch DM, Simmons NL, La Porte A, Riggs AM, Abbink P, Coffey RT, Grandpre LE, Seaman MS, Landucci G, Forthal DN, Montefiori DC, Carville A, Mansfield KG, Havenga MJ, Pau MG, Goudsmit J, Barouch DH.

Nature. 2009 Jan 1;457(7225):87-91. doi: 10.1038/nature07469. Epub 2008 Nov 9.

6.

Effect of neutralizing sera on factor x-mediated adenovirus serotype 5 gene transfer.

Parker AL, Waddington SN, Buckley SM, Custers J, Havenga MJ, van Rooijen N, Goudsmit J, McVey JH, Nicklin SA, Baker AH.

J Virol. 2009 Jan;83(1):479-83. doi: 10.1128/JVI.01878-08. Epub 2008 Oct 22.

7.

Trafficking of antigen-specific CD8+ T lymphocytes to mucosal surfaces following intramuscular vaccination.

Kaufman DR, Liu J, Carville A, Mansfield KG, Havenga MJ, Goudsmit J, Barouch DH.

J Immunol. 2008 Sep 15;181(6):4188-98.

8.

Serum-free transient protein production system based on adenoviral vector and PER.C6 technology: high yield and preserved bioactivity.

Havenga MJ, Holterman L, Melis I, Smits S, Kaspers J, Heemskerk E, van der Vlugt R, Koldijk M, Schouten GJ, Hateboer G, Brouwer K, Vogels R, Goudsmit J.

Biotechnol Bioeng. 2008 Jun 1;100(2):273-83. doi: 10.1002/bit.21757.

PMID:
18512821
9.

Differential antigen requirements for protection against systemic and intranasal vaccinia virus challenges in mice.

Kaufman DR, Goudsmit J, Holterman L, Ewald BA, Denholtz M, Devoy C, Giri A, Grandpre LE, Heraud JM, Franchini G, Seaman MS, Havenga MJ, Barouch DH.

J Virol. 2008 Jul;82(14):6829-37. doi: 10.1128/JVI.00353-08. Epub 2008 Apr 30.

10.

Magnitude and phenotype of cellular immune responses elicited by recombinant adenovirus vectors and heterologous prime-boost regimens in rhesus monkeys.

Liu J, Ewald BA, Lynch DM, Denholtz M, Abbink P, Lemckert AA, Carville A, Mansfield KG, Havenga MJ, Goudsmit J, Barouch DH.

J Virol. 2008 May;82(10):4844-52. doi: 10.1128/JVI.02616-07. Epub 2008 Mar 12.

11.

Adenovirus serotype 5 hexon mediates liver gene transfer.

Waddington SN, McVey JH, Bhella D, Parker AL, Barker K, Atoda H, Pink R, Buckley SM, Greig JA, Denby L, Custers J, Morita T, Francischetti IM, Monteiro RQ, Barouch DH, van Rooijen N, Napoli C, Havenga MJ, Nicklin SA, Baker AH.

Cell. 2008 Feb 8;132(3):397-409. doi: 10.1016/j.cell.2008.01.016.

12.

Impact of recombinant adenovirus serotype 35 priming versus boosting of a Plasmodium falciparum protein: characterization of T- and B-cell responses to liver-stage antigen 1.

Rodríguez A, Goudsmit J, Companjen A, Mintardjo R, Gillissen G, Tax D, Sijtsma J, Weverling GJ, Holterman L, Lanar DE, Havenga MJ, Radosevic K.

Infect Immun. 2008 Apr;76(4):1709-18. doi: 10.1128/IAI.01614-07. Epub 2008 Jan 22.

13.

Species B adenovirus serotypes 3, 7, 11 and 35 share similar binding sites on the membrane cofactor protein CD46 receptor.

Fleischli C, Sirena D, Lesage G, Havenga MJ, Cattaneo R, Greber UF, Hemmi S.

J Gen Virol. 2007 Nov;88(Pt 11):2925-34.

14.

High-level expression from two independent expression cassettes in replication-incompetent adenovirus type 35 vector.

Vogels R, Zuijdgeest D, van Meerendonk M, Companjen A, Gillissen G, Sijtsma J, Melis I, Holterman L, Radosevic K, Goudsmit J, Havenga MJ.

J Gen Virol. 2007 Nov;88(Pt 11):2915-24.

PMID:
17947512
15.

Increased immunogenicity of recombinant Ad35-based malaria vaccine through formulation with aluminium phosphate adjuvant.

Ophorst OJ, Radosević K, Klap JM, Sijtsma J, Gillissen G, Mintardjo R, van Ooij MJ, Holterman L, Companjen A, Goudsmit J, Havenga MJ.

Vaccine. 2007 Aug 29;25(35):6501-10. Epub 2007 Jun 29.

PMID:
17646036
16.

Myeloid and plasmacytoid dendritic cells are susceptible to recombinant adenovirus vectors and stimulate polyfunctional memory T cell responses.

Loré K, Adams WC, Havenga MJ, Precopio ML, Holterman L, Goudsmit J, Koup RA.

J Immunol. 2007 Aug 1;179(3):1721-9.

17.

Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D.

Abbink P, Lemckert AA, Ewald BA, Lynch DM, Denholtz M, Smits S, Holterman L, Damen I, Vogels R, Thorner AR, O'Brien KL, Carville A, Mansfield KG, Goudsmit J, Havenga MJ, Barouch DH.

J Virol. 2007 May;81(9):4654-63. Epub 2007 Feb 28.

18.

Influence of coagulation factor zymogens on the infectivity of adenoviruses pseudotyped with fibers from subgroup D.

Parker AL, McVey JH, Doctor JH, Lopez-Franco O, Waddington SN, Havenga MJ, Nicklin SA, Baker AH.

J Virol. 2007 Apr;81(7):3627-31. Epub 2007 Jan 24.

19.

Expression and immunogenicity of the Plasmodium falciparum circumsporozoite protein: the role of GPI signal sequence.

Ophorst OJ, Radosević K, Ouwehand K, van Beem W, Mintardjo R, Sijtsma J, Kaspers J, Companjen A, Holterman L, Goudsmit J, Havenga MJ.

Vaccine. 2007 Feb 9;25(8):1426-36. Epub 2006 Nov 7.

PMID:
17161889
20.

Human adenovirus type 35 vector for gene therapy of brain cancer: improved transduction and bypass of pre-existing anti-vector immunity in cancer patients.

Brouwer E, Havenga MJ, Ophorst O, de Leeuw B, Gijsbers L, Gillissen G, Hoeben RC, ter Horst M, Nanda D, Dirven C, Avezaat CJ, Goudsmit J, Sillevis Smitt P.

Cancer Gene Ther. 2007 Feb;14(2):211-9. Epub 2006 Nov 3.

PMID:
17082793
21.

Immunogenicity of heterologous recombinant adenovirus prime-boost vaccine regimens is enhanced by circumventing vector cross-reactivity.

Thorner AR, Lemckert AA, Goudsmit J, Lynch DM, Ewald BA, Denholtz M, Havenga MJ, Barouch DH.

J Virol. 2006 Dec;80(24):12009-16. Epub 2006 Oct 11.

22.

Age dependence of adenovirus-specific neutralizing antibody titers in individuals from sub-Saharan Africa.

Thorner AR, Vogels R, Kaspers J, Weverling GJ, Holterman L, Lemckert AA, Dilraj A, McNally LM, Jeena PM, Jepsen S, Abbink P, Nanda A, Swanson PE, Bates AT, O'Brien KL, Havenga MJ, Goudsmit J, Barouch DH.

J Clin Microbiol. 2006 Oct;44(10):3781-3.

23.

Generation of a novel replication-incompetent adenoviral vector derived from human adenovirus type 49: manufacture on PER.C6 cells, tropism and immunogenicity.

Lemckert AA, Grimbergen J, Smits S, Hartkoorn E, Holterman L, Berkhout B, Barouch DH, Vogels R, Quax P, Goudsmit J, Havenga MJ.

J Gen Virol. 2006 Oct;87(Pt 10):2891-9.

PMID:
16963747
24.

Viral vectors for malaria vaccine development.

Li S, Locke E, Bruder J, Clarke D, Doolan DL, Havenga MJ, Hill AV, Liljestrom P, Monath TP, Naim HY, Ockenhouse C, Tang DC, Van Kampen KR, Viret JF, Zavala F, Dubovsky F.

Vaccine. 2007 Mar 30;25(14):2567-74. Epub 2006 Aug 1. Review.

PMID:
16914237
25.

Intradermal delivery of adenoviral type-35 vectors leads to high efficiency transduction of mature, CD8+ T cell-stimulating skin-emigrated dendritic cells.

de Gruijl TD, Ophorst OJ, Goudsmit J, Verhaagh S, Lougheed SM, Radosevic K, Havenga MJ, Scheper RJ.

J Immunol. 2006 Aug 15;177(4):2208-15.

26.

Expression of aberrantly glycosylated tumor mucin-1 on human DC after transduction with a fiber-modified adenoviral vector.

van Leeuwen EB, Cloosen S, Senden-Gijsbers BL, Agervig Tarp M, Mandel U, Clausen H, Havenga MJ, Duffour MT, García-Vallejo JJ, Germeraad WT, Bos GM.

Cytotherapy. 2006;8(1):24-35.

PMID:
16627342
27.

Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity.

Roberts DM, Nanda A, Havenga MJ, Abbink P, Lynch DM, Ewald BA, Liu J, Thorner AR, Swanson PE, Gorgone DA, Lifton MA, Lemckert AA, Holterman L, Chen B, Dilraj A, Carville A, Mansfield KG, Goudsmit J, Barouch DH.

Nature. 2006 May 11;441(7090):239-43. Epub 2006 Apr 16.

PMID:
16625206
28.

Improved gene delivery to intestinal mucosa by adenoviral vectors bearing subgroup B and d fibers.

Lecollinet S, Gavard F, Havenga MJ, Spiller OB, Lemckert A, Goudsmit J, Eloit M, Richardson J.

J Virol. 2006 Mar;80(6):2747-59.

29.

Immunogenicity and protection of a recombinant human adenovirus serotype 35-based malaria vaccine against Plasmodium yoelii in mice.

Ophorst OJ, Radosević K, Havenga MJ, Pau MG, Holterman L, Berkhout B, Goudsmit J, Tsuji M.

Infect Immun. 2006 Jan;74(1):313-20.

30.

Immunogenicity of recombinant fiber-chimeric adenovirus serotype 35 vector-based vaccines in mice and rhesus monkeys.

Nanda A, Lynch DM, Goudsmit J, Lemckert AA, Ewald BA, Sumida SM, Truitt DM, Abbink P, Kishko MG, Gorgone DA, Lifton MA, Shen L, Carville A, Mansfield KG, Havenga MJ, Barouch DH.

J Virol. 2005 Nov;79(22):14161-8.

31.

Prospects for chimeric adenoviruses.

Havenga MJ, Vogels R, Bout A.

IDrugs. 2001 Feb;4(2):179-88. No abstract available.

PMID:
16032480
32.

Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity.

Lemckert AA, Sumida SM, Holterman L, Vogels R, Truitt DM, Lynch DM, Nanda A, Ewald BA, Gorgone DA, Lifton MA, Goudsmit J, Havenga MJ, Barouch DH.

J Virol. 2005 Aug;79(15):9694-701.

33.

Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein.

Sumida SM, Truitt DM, Lemckert AA, Vogels R, Custers JH, Addo MM, Lockman S, Peter T, Peyerl FW, Kishko MG, Jackson SS, Gorgone DA, Lifton MA, Essex M, Walker BD, Goudsmit J, Havenga MJ, Barouch DH.

J Immunol. 2005 Jun 1;174(11):7179-85.

34.

The dendritic cell-derived protein DC-STAMP is highly conserved and localizes to the endoplasmic reticulum.

Eleveld-Trancikova D, Triantis V, Moulin V, Looman MW, Wijers M, Fransen JA, Lemckert AA, Havenga MJ, Figdor CG, Janssen RA, Adema GJ.

J Leukoc Biol. 2005 Mar;77(3):337-43. Epub 2004 Dec 15.

PMID:
15601667
35.

An adenoviral type 5 vector carrying a type 35 fiber as a vaccine vehicle: DC targeting, cross neutralization, and immunogenicity.

Ophorst OJ, Kostense S, Goudsmit J, De Swart RL, Verhaagh S, Zakhartchouk A, Van Meijer M, Sprangers M, Van Amerongen G, Yüksel S, Osterhaus AD, Havenga MJ.

Vaccine. 2004 Aug 13;22(23-24):3035-44.

PMID:
15297053
36.

Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity.

Barouch DH, Pau MG, Custers JH, Koudstaal W, Kostense S, Havenga MJ, Truitt DM, Sumida SM, Kishko MG, Arthur JC, Korioth-Schmitz B, Newberg MH, Gorgone DA, Lifton MA, Panicali DL, Nabel GJ, Letvin NL, Goudsmit J.

J Immunol. 2004 May 15;172(10):6290-7.

37.

Neutralizing antibodies and CD8+ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors.

Sumida SM, Truitt DM, Kishko MG, Arthur JC, Jackson SS, Gorgone DA, Lifton MA, Koudstaal W, Pau MG, Kostense S, Havenga MJ, Goudsmit J, Letvin NL, Barouch DH.

J Virol. 2004 Mar;78(6):2666-73.

38.

Induction of CAMEL/NY-ESO-ORF2-specific CD8+ T cells upon stimulation with dendritic cells infected with a modified Ad5 vector expressing a chimeric Ad5/35 fiber.

Slager EH, van der Minne CE, Goudsmit J, van Oers JM, Kostense S, Havenga MJ, Osanto S, Griffioen M.

Cancer Gene Ther. 2004 Mar;11(3):227-36.

PMID:
14726960
39.

Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors.

Sprangers MC, Lakhai W, Koudstaal W, Verhoeven M, Koel BF, Vogels R, Goudsmit J, Havenga MJ, Kostense S.

J Clin Microbiol. 2003 Nov;41(11):5046-52.

40.

CD4+ Th2 cell recognition of HLA-DR-restricted epitopes derived from CAMEL: a tumor antigen translated in an alternative open reading frame.

Slager EH, Borghi M, van der Minne CE, Aarnoudse CA, Havenga MJ, Schrier PI, Osanto S, Griffioen M.

J Immunol. 2003 Feb 1;170(3):1490-7.

41.

Gene transfer of the urokinase-type plasminogen activator receptor-targeted matrix metalloproteinase inhibitor TIMP-1.ATF suppresses neointima formation more efficiently than tissue inhibitor of metalloproteinase-1.

Lamfers ML, Grimbergen JM, Aalders MC, Havenga MJ, de Vries MR, Huisman LG, van Hinsbergh VW, Quax PH.

Circ Res. 2002 Nov 15;91(10):945-52.

PMID:
12433840
42.

Odocoileus hemionus deer adenovirus is related to the members of Atadenovirus genus.

Zakhartchouk A, Bout A, Woods LW, Lehmkuhl HD, Havenga MJ.

Arch Virol. 2002 Apr;147(4):841-7.

PMID:
12038693
43.

Exploiting the natural diversity in adenovirus tropism for therapy and prevention of disease.

Havenga MJ, Lemckert AA, Ophorst OJ, van Meijer M, Germeraad WT, Grimbergen J, van Den Doel MA, Vogels R, van Deutekom J, Janson AA, de Bruijn JD, Uytdehaag F, Quax PH, Logtenberg T, Mehtali M, Bout A.

J Virol. 2002 May;76(9):4612-20.

44.

Highly efficient targeted transduction of undifferentiated human hematopoietic cells by adenoviral vectors displaying fiber knobs of subgroup B.

Knaän-Shanzer S, Van Der Velde I, Havenga MJ, Lemckert AA, De Vries AA, Valerio D.

Hum Gene Ther. 2001 Nov 1;12(16):1989-2005. Erratum in: Hum Gene Ther. 2003 Aug 10;14(12):1214.

PMID:
11686940
45.

Highly efficient transduction of human monocyte-derived dendritic cells with subgroup B fiber-modified adenovirus vectors enhances transgene-encoded antigen presentation to cytotoxic T cells.

Rea D, Havenga MJ, van Den Assem M, Sutmuller RP, Lemckert A, Hoeben RC, Bout A, Melief CJ, Offringa R.

J Immunol. 2001 Apr 15;166(8):5236-44.

46.

Strategies for improved antigen delivery into dendritic cells.

Rea D, Johnson ME, Havenga MJ, Melief CJ, Offringa R.

Trends Mol Med. 2001 Mar;7(3):91-4.

PMID:
11286763
47.

Infection efficiency of type 5 adenoviral vectors in synovial tissue can be enhanced with a type 16 fiber.

Goossens PH, Havenga MJ, Pieterman E, Lemckert AA, Breedveld FC, Bout A, Huizinga TW.

Arthritis Rheum. 2001 Mar;44(3):570-7.

48.

Improved adenovirus vectors for infection of cardiovascular tissues.

Havenga MJ, Lemckert AA, Grimbergen JM, Vogels R, Huisman LG, Valerio D, Bout A, Quax PH.

J Virol. 2001 Apr;75(7):3335-42. Erratum in: J Virol 2001 Jun;75(11):5440.

49.

Simultaneous detection of NOS-3 protein expression and nitric oxide production using a flow cytometer.

Havenga MJ, van Dam B, Groot BS, Grimbergen JM, Valerio D, Bout A, Quax PH.

Anal Biochem. 2001 Mar;290(2):283-91.

PMID:
11237331
50.

The influence of synovial fluid on adenovirus-mediated gene transfer to the synovial tissue.

Goossens PH, Vogels R, Pieterman E, Havenga MJ, Bout A, Breedveld FC, Valerio D, Huizinga TW.

Arthritis Rheum. 2001 Jan;44(1):48-52.

Supplemental Content

Loading ...
Support Center